Reshef, R., Jensen, A., Gordillo, C., Reid, B., Dima, D., Peres, L., Gaballa, M., Banerjee, R., Pasvolsky, O., Afrough, A., Dillard, C., Ferreri, C., Atrash, S., Varga, C., Portuguese, A., Rana, M., Hosoya, H., Mikkilineni, L., Hovanky, V., Zanwar, S., Kalariya, N., Mikulski, D., Wagner, C., Cahoon, C., Puglianini, O., Avila, G. D., Zolotov, E., Bhurtel, E., Grajales-Cruz, A., Goel, U., Sannareddy, A., Kort, J., Cassano, R., Midha, S., Davis, J., Gonzalez, R., Herr, M., Xie, Z., Hassan, H., Purvey, S., Geer, M., Green, K., Perna, F., Liu, H., Nishihori, T., Khouri, J., Raza, S., Anwer, F., Bal, S., Nadeem, O., Freeman, C. L., Shune, L., Shain, K., Alsina, M., Baz, R., Sborov, D., Dahiya, S., Locke, F., Miklos, D., Voorhees, P., Anderson, L., Costa, L., Biran, N., Kumar, S., Lin, Y., Patel, K., Hansen, D., Sidana, S. (2025). Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium. Blood. https://doi.org/10.1182/blood-2025-134